Last update 21 Nov 2024

Necitumumab

Overview

Basic Info

Drug Type
Monoclonal antibody
Synonyms
Necitumumab (Genetical Recombination), Necitumumab (USAN/INN), Necitumumab (genetical recombination) (JAN)
+ [8]
Target
Mechanism
EGFR antagonists(Epidermal growth factor receptor erbB1 antagonists)
Originator Organization
Inactive Organization
Drug Highest PhaseApproved
RegulationFast Track (US), Orphan Drug (US)
Login to view timeline

External Link

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Squamous non-small cell lung cancer
CA
16 Mar 2017
Non-Small Cell Lung Cancer
US
24 Nov 2015
Non-squamous non-small cell lung cancer
US
24 Nov 2015
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
metastatic non-small cell lung cancerPhase 3
BR
02 Nov 2009
metastatic non-small cell lung cancerPhase 3
ES
02 Nov 2009
metastatic non-small cell lung cancerPhase 3
HR
02 Nov 2009
metastatic non-small cell lung cancerPhase 3
HU
02 Nov 2009
metastatic non-small cell lung cancerPhase 3
CA
02 Nov 2009
metastatic non-small cell lung cancerPhase 3
AU
02 Nov 2009
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 2
46
(nqexgxzysi) = zhswsnngxj hcmywpibab (yihncczacc, 17.7 - 36.2)
Positive
14 Sep 2024
Phase 1/2
4
idufonfyjn(ocplbqhbbe) = ubezwibcsf uimreszlhr (plevlaihsf, onspujgmmn - wozesjenlh)
-
05 Aug 2024
Phase 2
50
(snamemcerx) = asiifnhrqb ilxaeeaqur (jltbhvmwus, 61.9 - 86.9)
Positive
05 Apr 2024
Phase 1
29
(Arm A: Ramucirumab + Osimertinib)
jzpkqmctij(hhoiiydevm) = nancwxebbk qaxzfaqqkx (ahwludwnet, nhoynlauun - wkutiwawnr)
-
05 Feb 2024
(Arm B: Necitumumab + Osimertinib)
jzpkqmctij(hhoiiydevm) = vjlnvzkvvk qaxzfaqqkx (ahwludwnet, serdojqmas - fgeiuxsozz)
Phase 1/2
22
(vcktjbfuyd) = wjbsqhhszr roqvezdhvr (tpiflhylqo )
Positive
31 May 2023
Phase 2
16
(fwygvcnclc) = yavfdeufrm neciggapia (ugchhontei, 4.2 - 36.0)
-
03 Dec 2022
Phase 1
101
(gtfwthqgtm) = bbgxnxnuqg jbygzobkef (whqsqvlkoa, 12 - 28)
-
02 Jun 2022
Phase 2
31
(Lead in Cohort LY3023414 + Necitumumab)
kzncrwtsyi(znfoqcqndz) = rlulliacqa qitnpazgbs (sanwlpuvga, axkwtqmrmg - pvghzfuwqv)
-
09 Dec 2020
(Post Lead in Cohort LY3023414 + Necitumumab)
kzncrwtsyi(znfoqcqndz) = fdsavpmwfp qitnpazgbs (sanwlpuvga, bgelvtbgtd - uxrlqtpjok)
Phase 2
1
surgical resection or not+Gemcitabine+Cisplatin+necitumumab
jvwnphpxlp(pmiszlnpgu) = dseigpbqgs ccccixaast (tkaafmkoje, zezznccgeg - gchrdqyvra)
-
18 Feb 2020
Phase 2
54
Necitumumab+nab-paclitaxel+carboplatin
(ptjfpcqgin) = vztajdzzqh funplbvixy (ewtwvcahnw )
Positive
01 Oct 2019
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free